Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies. | Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network
▻https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2720075
Findings In this observational study of 99 cancer drugs approved by the FDA from 1989 to 2017, the median income return by the end of 2017 was found to be $14.50 (range, $3.30-$55.10) for every $1 research and development spending. Many drugs, particularly biologics, continued to generate high-sales incomes for the originator companies after expiry of patents and exclusive marketing rights.